Article Type : Research Article
Authors : Haq MMU, Razzak MMU, Rahman MAU, Shahidulla SM
Keywords : Ethosomes; skin; Novel drug delivery; Vsicular lipid carrier; Ethanol
Traditional drug delivery (oral route), while having numerous advantages such as ease of administration, has problems such as limited bioavailability and frequent doses, both of which are challenging for patients (low patient compliance), and a high cost. To address all of these drawbacks, a unique drug delivery method with optimum therapeutic efficacy and safety, as well as regulated release to reduce the size and quantity of doses, is required. This can be accomplished by adopting vesicular formulations to bypass these limitations and thereby improve medication delivery through the skin. Ethosomes are non-invasive drug delivery devices that allow medications to go deep into the skin's layers and into the bloodstream. Ethosomes are malleable, flexible vesicles that are used to optimise the administration of active agents. Ethosomes may encapsulate and transmit very lipophilic compounds, as well as cationic medicines, through the skin due to their unique structure. Ethosomal systems are a new concept.
The skin is the body's largest and most easily
accessible organ, and it may be used to provide drugs with systemic effects.
However, the stratum corneum, the outer layer of the skin, is the most
resistant barrier to drug penetration through the skin, limiting medication
transdermal bioavailability. To overcome the natural skin barrier and transfer
medication molecules with various physicochemical characteristics to the
systemic circulation, specific carriers are required [1,2]. Transdermal
delivery of drugs and vaccines is a feasible alternative to oral and parenteral
administration. It is feasible to prevent the liver's "first-pass"
inactivation, decrease gastrointestinal pain, ensure uniform drug absorption over
long periods of time, and reduce dose frequency, all of which promote adhesion
[3].
The transdermal method has gained popularity due to
its vast surface area and features that make medication administration easier.
Novel Carriers as Skin Permeability
Modification Tools
Effective barrier that protects the insides of our
bodies safe while keeping the outside out. The most significant condition and
aim for transdermal delivery is to modify this barrier feature, which includes
permeability to medicines, chemicals, and bioactive substances. As a result, a
variety of methods for increasing the penetration rate of various substances
have been tested. One of the options is to use innovative carriers capable of
controlled release, drug delivery at a predefined rate, and targeted delivery.
This might lead to improved efficacy, security, and patient compliance. For
efficient cutaneous and transdermal administration, micro particles,
nanoparticles, liposomes, elastic liposomes, noisome, ethosomes, and other new
delivery methods or carriers are used. Stable, non-toxic, non-immunogenic, and
cost-effective administration techniques are preferred. Pharmaceutically
acceptable, stable, biocompatible, and patient-friendly technologies are also
required [4-9].
Ethosomes
Ethosomes are soft and pliable ethanolic phospholipid
vesicles. They're made to make it easier to distribute agents. Because the skin
lipid bilayer organisation is disrupted when ethanol is introduced to a
vesicular membrane, it improves the vesicle's capacity to pass through the SC
[10]. The lipid membrane in SC lipids is less densely packed than in typical
vesicles, yet it is equally stable and improves drug delivery potential [11].
This non-invasive extended delivery system may also be utilised to disseminate
cultured cells and microbes. Using an Ethosomal carrier to increase bioactive
molecule distribution through the epidermal and cellular membranes poses a
number of obstacles as well as opportunities for future study and development
of innovative enhanced therapeutics [12-14]. Ethanolic liposomes, also known as
ethosomes, are lipid-based delivery vehicles that allow physiologically active
substances to reach deeper layers of the skin and/or circulate throughout the
body. Phospholipids are a kind of lipid found in the body [15-18].
Benefits of Ethosomal Drug Delivery
·
It is possible to
transmit large molecules (peptides, protein molecules).
·
The raw materials used in
the formulation are non-toxic.
·
Transdermal medication
administration requires improved drug penetration through the skin.
Pharmaceuticals, veterinary medicine, and cosmetics are just a few of the
applications for the Ethosomal drug delivery method.
·
Patient compliance is
good due to the fact that the ethosomal medication is supplied in a semisolid
form (gel or cream).
·
In compared to
Iontophoresis, Phonophoresis, and other sophisticated drug delivery systems,
this is a simple procedure.
·
The ethosomal system is a
passive, non-invasive method [19].
·
Encapsulation of the
medicine in its vesicular structures can be predicted to lengthen the drug's
life in systemic circulation and reduce toxicity if selective absorption can be
achieved. Compared to standard drug delivery systems, it provides a number of
benefits [20,21].
Disadvantages of Ethosomal Drug Delivery
·
Ethosomal administration
isn't meant to administer a bolus of medication all at once; rather, it's meant
to deliver a steady stream of medication over time.
·
Adequate drug solubility
in both lipophilic and lipophobic conditions allows drugs to penetrate the
dermal microcirculation and circulatory system.
·
The drug should have a
molecular size that allows it to be absorbed via the skin.
·
All skin types may or may
not adhere well to adhesive.
·
It won't be
cost-effective.
·
The return yield is
minimal.
·
Skin irritation or
dermatitis of the medication distribution structure can be caused by excipients
and enhancers.
·
When Ethosomes are placed
into water and the shell locking fails, the Ethosomes agglomerate and fall
apart.
·
During the shift from
organic to aqueous medium, there is a loss of product.
The main benefit of ethosomes over liposomes is their
smaller size, which allows for more drug penetration [22-27].
Composition of Ethosomes
The bulk of Ethosomes are made up of phospholipids
(phosphatidylcholine, phosphatidylserine, and phosphatidic acid), ethanol, and
water. Water makes up between 22 and 70 percent of the nonaqueous phase. The
alcohol might be either ethanol or isopropyl alcohol. Because ethanol is known
for damaging the tissue of the skin's lipid bilayer, ethosomes contain a high
ethanol content. When integrated into the membrane of a vesicle, it allows the
vesicle to burst through the stratum corneum. Because of the high ethanol
concentration, the lipid membrane is packed less densely than typical vesicles,
yet it has the same strength. It improves structural stability and makes the
structure more pliable. The ability of lipids in the stratum corneum to
transport medicines many types of additives utilised in the ethosomes
preparations [28-38].
Types of Ethosomal Systems
·
Classical ethosomes:
Classical ethosomes are a kind of liposome that includes phospholipids, water,
and high ethanol concentrations of up to 45 percent by weight. Because they
were smaller and had a negative charge, traditional ethosomes were considered
to be superior to traditional liposomes for transdermal medication delivery. It
is possible to boost productivity without cluttering. Classic ethosomes also
showed superior skin penetration and stability profiles than regular liposomes.
The molecular weights of drugs captured in typical ethosomes ranged from
130.077 Da to 24 kDa.
·
Binary ethosomes are a
kind of ethosome that has two copies. Binary ethosomes were implemented by Zhou
et al. We were created by adding a certain sort of alcohol to the mixture. The
antiquity ethosomes: Propylene glycol (PG) and isopropyl alcohol (IPA) are the
most often utilised alcohols in binary ethosomes.
·
Transethosomes are the
newest generation of ethosomal structures, as found by Song et al. in 2012.
Traditional ethosomes, as well as an extra substance such as a penetration
enhancer or an edge activator, are the basic components of this ethosomal
structure (surfactant). These unique vesicles were produced as a result of
transethosomes, which aimed to combine the advantages of regular ethosomes with
the deformability of deformable liposomes (transfersomes) in a single formula.
Transethosomes have been demonstrated to have better qualities than traditional
ethosomes in several research. Various forms of edge activators and penetration
enhancers were researched in order to develop better characteristic ethosomal
systems. Contains transethosomes. At molecular weights ranging from 130.077 Da
to 200–325 kDa, drug entrapment has been discovered [30].
Mechanism of Skin Penetration
·
Although the specific
mechanism of medication delivery via ethosomes is unknown, the presence of a
high quantity of ethanol distinguishes the ethosomes, as ethanol is known to
disrupt skin lipid bilayer structure. According to Touitou et al. (2000), ethanol,
vesicles, and skin lipids have a synergistic relationship that leads to a more
favourable permeability profile. When incorporated into a vesicle membrane, it
allows the vesicle to pass through the stratum corneum.
·
Ethanol interacts with lipid
molecules in the polar hard group area, lowering the transition temperature
(Tm) and enhancing the fluidity of stratum corneum lipids. Soft, pliable
ethosomes may be able to penetrate deeper into the epidermal layers through
this transition [31,32].
After topical application, Ethosomes improve
penetration significantly more than pure ethanol, revealing a synergistic
process involving ethanol, vesicles, and skin lipids [34]. The main benefit of
ethosomes over liposomes is that they allow for greater drug penetration. It's
unknown how ethosomes are absorbed, which is one of the drug's mechanisms. The
two steps of drug absorption that are most likely to happen are:
1. Ethanol effect:
Ethanol aids in the penetration of goods into the skin. It has a
well-understood mechanism for improving penetration. Intercellular lipids are
penetrated by ethanol, which boosts their concentration. Reduce the density of
the cell membrane's lipid multilayer and increase the fluidity of cell membrane
lipids.
2. Ethosomes effect:
Increased cell membrane lipid fluidity, which is generated by ethanol in
ethanol, leads to increased skin permeability. As a result, ethosomes penetrate
deep into the epidermal layers swiftly. It attaches to skin lipids and releases
medications when it comes into contact with them [35].
Method of Preparation
Ethosomes may be made in two ways that are both easy
and convenient [36,37].
1. Cold method:
It is the most often used method for ethosomal formulation production.
Phospholipids, drugs, and other lipid compounds are dissolved in ethanol in a
covered jar at room temperature using a mixer and rapid agitation. During the
stirring process, propylene glycol or another polyol is introduced. In a water
bath, this combination is heated to 300°C. In a separate pot, heat the water to
300°C and add it to the mixture, which is then agitated for 5 minutes in a
covered vessel. The vesicle size of ethosomal preparations can be lowered using
sonication or extrusion procedures to obtain the appropriate expansion.
Finally, the mixture is placed in the refrigerator [38-40].
2. Hot method:
The phospholipids are dispersed in water using this process, which involves
heating them in a water bath at 400°C until they become a colloidal solution.
Ethanol and propylene glycol are combined in a separate vessel and heated to
400 degrees Celsius. The organic phase is introduced to the aqueous phase after
both solutions reach 400°C. Depending on the drug's hydrophilic/hydrophobic
qualities, it's dissolved in water or ethanol. Using probing sonication or the
extrusion approach, the vesicle size of an ethosomal formulation may be reduced
to the desired level.
Method of Characterizations of Ethosomal
Formulation [41,42]
Vesicle
shape: Ethosomes can also be seen using
transmission electron microscopy (TEM) and scanning electron microscopy (SEM)
(SEM). To see what was going on, electron microscopy was utilised, which
revealed that an ethosomal formulation had a vesicular structure with a
diameter of 300-400 nm. Because of their asymmetrical spherical shape, the
vesicles appear flexible.
Vesicle
size and Zeta potential: Particle size and zeta
potential may be determined using dynamic light scattering (DLS) using a
computerised inspection approach and photon correlation spectroscopy (PCS).
Drug
entrapment: The ultracentrifugation technique may
be used to determine the entrapment effectiveness of ethosomes.
Entrapment Efficiency = [?Q t ? Q s ? ÷ Q t] × 100
Where,
Qt is the amount of drug added
Qs Is the amount of drug detected in the
supernatant?
Transition
Temperature: Differential scanning calorimetry
may be used to estimate the transition temperature of vesicular lipid systems.
Drug
content: A UV spectrophotometer may be used to
assess the drug content in ethosomes. A modified high-performance liquid
chromatographic technique can also be used to measure this.
Surface
tension measurement: The ring technique in a
Du Nouy ring tensiometer can be used to determine the surface tension activity
of a medication in aqueous solution.
Stability
studies: The size and shape of vesicles over time
can be used to determine their stability. DLS is used to determine the average
size, while TEM 8 is used to determine the structural change. Experiments on
skin permeation: Confocal laser scanning microscopy can be used to assess the
ethosomal preparation's capacity to penetrate into the epidermal layers (CLSM).
Evaluation of Ethosomes
Filter Membrane-Vesicle
Interaction Study by Scanning Electron Microscopy [SEM]
It necessitates vesicle suspension filtration (0.2
mL). In diffusion cells, a membrane with a whole size of 50 nm is placed. The
top of the filter is exposed to the sun. The top side should be exposed to
sunshine, while the bottom should be immersed in a phosphate saline buffer
solution (having pH 6.5). After 1 hour, the filters are removed, and the
samples are prepared for SEM examinations by overnight fixation in Karnovsky's
fixative at 4°C, followed by dehydration with ethanol solutions of varied concentrations
(30%, 50%, 70%, and 80%) in water (90%, 95%). The filters are then mounted,
gold-coated, and evaluated under a scanning electron microscope [SEM].
Skin Permeation, Studies
The test animals' hair was cut short (approximately 2
mm) using scissors, and the abdomen skin was removed from the underlying
connective tissue with a knife. The skin that had been excised was placed on
aluminium foil, and any adhering skin was gently teased off using the dermal
side of the skin (fat and/or subcutaneous tissue may be involved). The
effective permeation area and receptor cell volume of the diffusion cell were
1.0 cm2 and 10 mL, respectively. The temperature was held at 320C.
The temperature is -10C. In the receptor compartment, which contains
a saline solution, phosphate buffer was retained (10 mL at pH 6.5). Between the
donor's compartment and the receiver's compartment, the skin that had been
taken had been mounted. An ethosomal formulation (1.0 mL) was applied to the
epidermal surface of the skin. An ethosomal formulation (1.0 mL) was applied to
the epidermal surface of the skin. Samples (0.5 mL) were obtained using the
sampling system. A high-performance liquid chromatography equipment was used to
analyse the data.
Stability Study
The vesicles' stability was tested by storing them at
4°C + 0.5°C. After 180 days, the vesicles' size, zeta potential, and entrapment
efficiency were evaluated using the method described before.
Turbidity measurement
The Digital Nephalo-Turbidity Meter was used to
determine the turbidity of all of the ethosomal suspensions. The 500 NTU
(turbidimetric turbidity unit) range is used in this procedure, with Millipore
water as the zero reading. In a 50 mL glass cuvette, the ethosomal formulations
were transferred. The holder was then put into the instrument. The turbidity
reading was shown on the screen and represented in NTU.
In-vitro release via
dialysis membrane
This experiment was carried out using a Franz
Diffusion cell. The dialysis membrane was soaked overnight in phosphate buffer
7.4. Between the donor and receiver chambers, the dialysis membrane was clamped
down. 5 ml of the ethosomal formulation were uniformly distributed in the donor
compartment. 125 mL of phosphate buffer 7.4 was introduced to the receiver
compartment. Throughout the experiment, it was stirred continuously at 600 rpm
with a Teflon coated magnetic bead, and the temperature was held at 370 ± 0.5?.
To maintain the sink condition, 5 ml of the receiver fluid was withdrawn at
each 1-hour interval and refilled with the same amount. A UV spectrophotometer
was used to determine the drug content of withdrawn samples.
1. Prausnitz
MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008; 26: 1261-1268.
9. Benson HAE.
Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv. 2006; 3:
727-737.
16. Touitou
E, Alkabes M, Dayan N. Ethosomes: Novel lipid vesicular system for enhanced
delivery. Pharm Res. 1997; 14: 305-306.
23. Upadhyay
N, Mandal S, Bhatia L, Shailesh S, Chauhan P. A Review on Ethosomes: An
emerging approach for drug delivery through the skin. Recent Res Sci Technol.
2011; 3: 19-24.
24. Sivakranth
M, AnjumaAra P, Krishnaveni C, Venkatesh E. Ethosomes: A novel vesicular drug
delivery system. Int J Advances Pharmaceutical Res. 2012; 2: 16-27.
25. Kumar
R, Aslam MD, Tripathi A, Prasad D, Chaudhary V, Jain V, et al. Ethosomes: Novel
Vesicular carriers in transdermal drug delivery. J Global Pharma Tech. 2010; 2:
1-7.
26. Rathore
AR, Khambete H, Jain S. Preparation and characterization of repaglinide loaded
ethosomal gel for the treatment of NIDDM. Int J Pharmaceutical Biological
Archives. 2013; 4: 385-390.
27. Shahwal
V, Samnani A, Dubey B, Bhowmick M. Ethosomes: An overview. Int J Biomedical
Advance Res. 2011; 2: 161-168.
28. Touitou
E. Drug delivery across skin. Expert Opinion Biological Therapy. 2002; 2:
723-733.
33. Charyulu
RN, Harish NM, Sudhakar CK, Udupa G. Formulation and evaluation of clotrimazole
ethosomes for topical delivery. AAPS Annual Meeting Expo. 2009; 7-12.
39. Touitou
E. Composition of Applying Active Substance to or Through the Skin. US patent.
1998.
41. Rathore
AR, Khambete H, Jain S: preparation and characterization of repaglinide loaded
ethosomal Gel for the treatment of NIDDM. Int J Pharm Biological Archieves.
2013; 4: 385-390.
42. Sheer
A. Chauhan M: Ethosomes as vesicular carrier for enhanced transdermal delivery
of Ketoconazole- formulation and evaluation. J Pharm Cosmetology. 2011; 1:
1-14.